Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Veterans General Hospital.
• Treatments: Famotidine; Histamine; Histamine H2 Antagonists; Histamine phosphate; Pantoprazole; Proton Pump Inhibitors

Criteria

Inclusion Criteria:

• Recent endoscopic examination (within 2 months) reveals normal appearance or erythematous patches only (without subepithelial hemorrhages, erosions or ulcers).

• Peptic ulcers (a mucosal break ³ 5 mm in diameter) have been documented by a previous endoscopic examination.

• Subjects have received thienopyridine therapy for at least two weeks.

• Requiring long-term anti-platelet therapy for ischemic cardiovascular diseases.

Exclusion Criteria:

• A history of gastric or duodenal surgery other than oversewing of a perforation.

• Subjects who are allergic to the study drugs.

• Requiring long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, aspirin, or anticoagulant agents.

• Pregnancy.

• Subjects who have active cancer, acute serious medical illness or terminal illness.

• Subjects who have gastroesophageal reflux disease.